Reduced concentrations of selenium in the blood of breast cancer patients [144] and the established anticancer properties of selenium (e.g., exerting oxidative stress in tumor tissues, reducing tumor growth and metastasis, decreasing VEGF expression, enhancing immune resistance, and diminishing antitumor drug resistance) suggest that selenium could be an apt treatment for TNBC patients [137,145]. Here, VEGFA is linked to neoplasm.